The CDMO market serves eight primary customer types—from Fortune 500 pharmaceutical companies to biotech startup teams—each with fundamentally different procurement strategies, decision-making criteria, and expectations. Understanding customer segments is essential for two reasons. First, if you are a CDMO provider, your sales, marketing, and service delivery must align with your target customer segment—selling to a startup biotech team requires different messaging and support than selling to large pharma procurement. Second, if you are a pharma company evaluating CDMO partnerships, understanding how companies like yours approach supplier selection and negotiation helps you benchmark your procurement practices.
The CDMO customer landscape is bifurcating. Large pharmaceutical companies (45% of demand) are consolidating supplier relationships and shifting toward efficiency gains. Biotech companies (28% of demand) are expanding rapidly and depend on CDMO services as core infrastructure. This divergence means that overall market growth is driven increasingly by biotech expansion, not large pharma scale. For investors evaluating CDMO providers, this shift has profound implications: CDMOs with strong biotech customer relationships are positioned for higher growth and better long-term valuations than those dependent on large pharma relationships.
Large pharmaceutical companies (Roche, Merck, Johnson & Johnson, AbbVie, Eli Lilly, Novartis, Sanofi) use CDMOs strategically for non-core products and capacity overflow, not for core portfolio manufacturing.
Procurement Strategy: Large pharma maintains a centralized procurement function (often a single executive overseeing all CDMO supplier relationships across the company). Procurement follows formal evaluation processes: request for proposals (RFPs), 6-12 month due diligence including facility audits, regulatory compliance verification, and quality assessments. Once approved, suppliers enter "preferred supplier" status for 3-5 years. This structure creates strong switching costs and relationship stability.
Supplier Selection Criteria (Ranked):
Contract Structure: Long-term agreements (3-5 years) with volume commitments. Contracts typically specify: cost per unit (fixed or tied to cost indices), minimum and maximum annual volumes, capacity reservation, quality specifications, and regulatory compliance requirements. Price renegotiation occurs at contract renewal—large pharma negotiating leverage increases if CDMO capacity is not fully utilized.
Supply Chain Model: Most large pharma companies maintain a "2-3 supplier" model for critical products: primary CDMO (70-80% volume), secondary supplier (20-30% volume) to ensure supply continuity. This hedges supply chain risk while maintaining CDMO pricing discipline.
Decision-Making Timeline: Long and complex—6-12 month evaluation, 2-4 month procurement/contracting, 3-6 month relationship establishment before first manufacturing. Total time from RFP to first production batch: 12-20 months. Patience and relationship development are critical for CDMO sales teams targeting large pharma.
Procurement Team Composition: Chief Procurement Officer (strategic oversight), Procurement Directors (CDMO relationship management), Supply Chain Specialists (logistics, cost management), Quality Assurance Representatives (regulatory compliance, audit participation), R&D/Operations Representatives (technical input on manufacturing approach). Large pharma procurement involves 5-8 stakeholders with distinct perspectives; CDMOs must address all stakeholder concerns during evaluation.
Relationship Dynamics: Transactional. Large pharma companies negotiate aggressively on price once primary supplier selection is complete. They expect continuous cost reduction (2-5% annually) and continuous quality improvement. CDMO responsiveness must be excellent; large pharma companies have low tolerance for manufacturing delays or quality issues. However, once approved, relationships are sticky—switching costs and qualification delays make supplier transitions unlikely unless major performance issues emerge.
Risk Profile for CDMO: Large pharma customers provide significant volume and stable revenue, but negotiate aggressively on price and margins. They maintain alternative suppliers, creating continuous pricing pressure. However, volume scale and payment reliability (large pharma companies pay invoices reliably) make them valuable customers. CDMO focus with large pharma should be: operational excellence, continuous cost reduction without quality compromise, and reliable delivery.
Mid-sized pharma companies (Hikma, Teva divisions, Endo Pharmaceuticals, specialty pharma companies) use CDMOs for the majority of manufacturing, including core products.
Procurement Strategy: Procurement is typically managed by single supply chain manager or small team (2-3 people). Decision-making is faster than large pharma but more formal than biotech. Evaluation involves site visits, quality audits, and regulatory compliance verification. Decisions are made by supply chain and operations leadership with less centralized governance than large pharma.
Supplier Selection Criteria (Ranked):
Contract Structure: Medium-term agreements (2-3 years, sometimes 3-5 years). Contracts often specify base cost with volume incentives (cost reduction at higher volumes). Contracts are less complex than large pharma but more formalized than biotech startups. Price negotiation occurs but is less adversarial than large pharma relationships.
Supply Chain Model: Most mid-sized companies maintain single-source relationships for established products (to ensure regulatory stability) but seek backup suppliers for new products in development. Single-source relationships reduce supply chain complexity.
Decision-Making Timeline: Moderate—3-6 month evaluation, 1-2 month contracting, 1-3 month relationship establishment. Total time from initial inquiry to production: 6-12 months (faster than large pharma).
Procurement Team Composition: Supply Chain Director or VP (decision authority), Procurement Manager (relationship management), Quality/Operations Representatives (technical input). Typically 3-4 decision-makers with more streamlined approval process than large pharma.
Relationship Dynamics: Collaborative. Mid-sized pharma companies seek partnership relationships with strong CDMO responsiveness. They are willing to pay fair prices for reliable service and technical support. However, they also expect continuous improvement and cost management. CDMO-customer relationships with mid-sized pharma are often warmer and more personal than large pharma (fewer organizational layers).
Risk Profile for CDMO: Mid-sized pharma customers provide stable, reliable volume with reasonable margins. Price competition is moderate. However, customers are more financially sensitive than large pharma—if customer's product faces commercial challenges, CDMO volume may decline rapidly. CDMO focus should be: technical support, operational reliability, and flexibility to accommodate scaling needs.
Small pharmaceutical companies (<500 employees) and startups (often <100 employees) lack internal manufacturing infrastructure and depend on CDMOs for all API manufacturing.
Procurement Strategy: Procurement is typically handled by single Operations or Supply Chain Manager (sometimes even the CEO for very small companies). Decision-making is fast and informal—days to weeks for evaluation, weeks to months for contracting. There is minimal formal due diligence; instead, personal relationships and referrals are critical decision drivers. Small pharma companies rely heavily on recommendations from other biotech companies, industry conferences, and regulatory consultants when selecting CDMOs.
Supplier Selection Criteria (Ranked):
Contract Structure: Short- to medium-term agreements (1-3 years) with milestone-based pricing. Small pharma companies are capital-constrained and prefer to pay manufacturing fees tied to project milestones (IND approval, Phase I completion, Phase III enrollment, FDA approval) rather than fixed annual fees. CDMO willingness to accommodate milestone-based pricing is critical for small pharma relationships. Contracts are often less formal and legally complex than large/mid-sized pharma contracts.
Supply Chain Model: Single CDMO partnership. Small pharma companies cannot maintain multiple suppliers. They rely on single CDMO for all manufacturing needs.
Decision-Making Timeline: Fast—1-2 month evaluation including reference checks and informal due diligence, 1-2 month contracting. Total time from inquiry to contract signature: 2-4 months. However, relationship establishment and first manufacturing batch may extend overall timeline.
Procurement Team Composition: Operations Manager, Supply Chain Manager, or even the CEO (for very small companies). Often includes input from company's regulatory consultant (external). Typically 1-2 decision-makers. Board/investor input may be required if manufacturing decisions represent significant company expense.
Relationship Dynamics: Partnership-oriented. Small pharma companies view their CDMO partner as an extension of internal capabilities—essentially outsourced manufacturing operations. They expect significant hand-holding, technical support beyond manufacturing execution, regulatory guidance, and flexibility to accommodate evolving product development timelines. CDMO responsiveness and technical collaboration are highly valued. Small pharma customers develop strong personal relationships with CDMO technical teams and expect availability and quick turnaround.
Risk Profile for CDMO: Small pharma customers provide modest volume but offer strategic advantages:
(1) They represent entry points into biotech customer relationships if their products succeed and scale to larger volumes,
(2) They develop strong personal relationships and loyalty if service is excellent,
(3) Successful small pharma products can become significant revenue sources.
However, risks include the following:
(1) Many small pharma companies fail.
(2) Successful products may transition to larger CDMOs as scale increases.
(3) Payment reliability is lower than large/mid-sized pharma.
CDMO focus should be technical support, relationship development, flexible milestone-based pricing, and willingness to invest in early-stage relationships with potential long-term upside.
Biotech companies represent the fastest-growing CDMO customer segment and are the primary drivers of overall CDMO market expansion.
Procurement Strategy: Procurement is typically managed by VP or Director of Operations or Manufacturing (no dedicated procurement function in many biotech companies). Decision-making is collaborative, involving founders/CEO, VP Operations, and sometimes scientific advisors. Biotech companies conduct moderate due diligence: site visits, reference calls (often to other biotech companies), and regulatory compliance verification. Speed is critical—biotech companies are time-constrained and expect CDMO evaluation and contracting within weeks, not months.
Supplier Selection Criteria (Ranked):
Contract Structure: Medium- to long-term agreements (3-5 years, sometimes extending 7-10 years as biotech companies grow). Milestone-based pricing is common (early stages), transitioning to volume-based pricing at commercial stage. Contracts emphasize flexibility: provisions for timeline adjustments, process changes, and scale modifications as product development evolves. Risk-sharing mechanisms are common (e.g., CDMO shares in regulatory milestone success).
Supply Chain Model: Single integrated CDMO partnership. Most biotech companies cannot maintain multiple suppliers—their volume and resources are concentrated with one CDMO. However, some mature biotech companies (with successful products) maintain dual suppliers for supply chain risk mitigation.
Decision-Making Timeline: Fast—2-4 week evaluation including reference checks, 1-2 week contracting. Total time from inquiry to contract: 3-6 weeks. Biotech companies value speed and are impatient with slow CDMO evaluation processes.
Procurement Team Composition: CEO/Founder (investment authority), VP Operations or Manufacturing (technical evaluation), Scientific Advisory Board members (external validation). Often 3-5 decision-makers but structure is more fluid than large/mid-sized pharma. Board investors may have veto authority on significant manufacturing partnerships.
Relationship Dynamics: Deep partnership. Biotech companies view CDMO relationships as core operational partnerships—not vendor relationships. They expect:
(1) Technical collaboration and problem-solving.
(2) Regulatory guidance throughout development.
(3) Flexibility to accommodate development timelines.
(4) Transparency into manufacturing operations and progress.
(5) Proactive communication and early warning of potential issues.
CDMO technical teams become extensions of biotech company operations. Personal relationships between CDMO scientists and biotech company founders are often critical to relationship quality.
Risk Profile for CDMO: Biotech customers create the highest lifetime value for CDMOs—relationships span 8-12+ years from early development through commercial production and ongoing lifecycle management. However, risks include:
(1) Many biotech products fail (CDMO relationship ends if product is discontinued).
(2) Biotech companies sometimes transition to larger CDMOs as products scale.
(3) Venture capital funding changes can impact customer priorities.
CDMO focus should be: deep technical collaboration, regulatory expertise, flexibility and responsiveness, and relationship development at founder/CEO level.
Strategic Importance: Biotech customers represent the strategic future of CDMO market growth. Leading CDMO providers are increasingly focused on biotech customer acquisition and deepening biotech relationships. CDMOs with strong biotech customer concentration are positioned for higher growth rates and better investor valuations than those dependent on large/mid-sized pharma.
Generic pharmaceutical manufacturers (Teva, Mylan, Hikma, Cipla, other generics) use CDMOs for manufacturing capacity during patent cliff transitions and specialized capability for complex generics.
Procurement Strategy: Procurement follows formal processes similar to large pharma: RFPs, facility audits, cost comparison. Generics manufacturers are highly price-sensitive and conduct detailed cost-benefit analysis on outsourcing vs. internal manufacturing decisions.
Supplier Selection Criteria (Ranked):
Contract Structure: Short- to medium-term agreements (1-3 years) with high volume commitments. Price is heavily negotiated and forms the centerpiece of contract terms. Cost reduction clauses are standard.
Relationship Dynamics: Transactional. Generics manufacturers view CDMOs as cost centers and negotiate aggressively. Loyalty is minimal; suppliers are changed if better cost terms are available elsewhere. However, volume scale can be significant (generics are high-volume products).
Risk Profile for CDMO: Generics customers provide high volume but pressure margins aggressively. CDMO relationships are unstable (prone to switching). However, cost-competitive CDMOs with significant scale can serve generics profitably. CDMO focus should be: operational efficiency, cost optimization, and reliable delivery at scale.
Specialty pharma companies focus on specific therapeutic area demand for CDMO services or drug types (e.g., specialty oncology, rare disease, biologics-focused companies).
Procurement Strategy: Procurement approach is similar to mid-sized pharma: moderate evaluation, relationship-focused partnerships. Specialty pharma companies seek CDMOs with deep expertise in their therapeutic niche.
Supplier Selection Criteria:
Relationship Dynamics: Collaborative. Specialty pharma companies seek long-term CDMO partnerships focused on technical excellence, not lowest cost. Relationships tend to be stable and quality-focused.
CROs conducting clinical trials and drug development services increasingly use CDMOs for manufacturing clinical trial supplies and early-stage manufacturing support.
Procurement Strategy: CROs conduct rapid evaluation focused on speed, flexibility, and cost management. CROs pass through manufacturing costs to their biotech/pharma clients, creating focus on cost efficiency.
Key Dynamics: CROs represent secondary market channel for CDMO services. CRO relationships can lead to direct biotech company relationships if drug candidates succeed. Growth is being driven by expansion of clinical trial outsourcing.
Universities and research institutions use CDMOs for manufacturing experimental compounds and supporting drug discovery research.
Procurement Strategy: Academic procurement is limited by research funding constraints. Cost is primary driver. Relationships are project-based and time-limited.
Strategic Value: Small absolute value but strategically important as source of innovation and early-stage drug discovery. Successful academic discoveries often transition to biotech startup formation, creating future CDMO customers.
These evolving outsourcing strategies and customer preferences are explored in greater detail within the latest API CDMO Industry Analysis.
Biotech Customer Focus: Biotech represents the highest-growth, highest-value customer segment. Leading CDMO providers are investing heavily in biotech capabilities, marketing, and customer relationships. If you are evaluating CDMO investment opportunities, prioritize providers with strong biotech customer concentration.
Large Pharma Volume + Biotech Growth: Optimal portfolio strategy balances large pharma volume (provides scale and revenue stability) with biotech growth (provides margin expansion and valuation multiple support). CDMOs dominated by single customer type face risks: large-pharma-only providers face margin compression; biotech-only providers face volume volatility.
Customer Acquisition Economics: Small pharma/startup customers represent acquisition cost investments with delayed return. However, successful small pharma products scale into significant revenue streams and develop strong customer loyalty. Strategic CDMO providers accept near-term low margins on small pharma relationships to build future large relationships.